Basic Science and Pathogenesis.

Area of Science:

• Neuroscience
• Pathology
• Human Brain Studies

Background:

• Selective neuronal vulnerability is crucial for understanding Alzheimer's disease (AD) pathogenesis and progression.
• The anterior hypothalamus, particularly the suprachiasmatic nucleus (SCN), plays a key role in circadian control and is investigated for AD vulnerability.
• Arginine vasopressin-expressing (AVP+) neurons in the SCN, paraventricular nucleus (PVN), and supraoptic nucleus (SON) are central to circadian function.

Purpose of the Study:

• To assess if the SCN, PVN, and SON serve as a platform for studying selective neuronal vulnerability in Alzheimer's disease.
• To quantify neuronal populations and Alzheimer's disease pathology burden in these specific hypothalamic nuclei.

Main Methods:

• Analysis of postmortem anterior hypothalamic tissue (SCN, PVN, SON) from 12 controls and 28 AD cases (Braak stages I, II, VI).
• Quantification of arginine vasopressin-expressing (AVP+) neurons using fluorescence in situ hybridization.
• Assessment of amyloid plaques and neurofibrillary tangles using 2D image registration on adjacent sections.

Main Results:

• Significant AVP+ neuronal loss observed in the SCN by Braak stage II, with stable populations in the PVN and SON.
• Phosphorylated tau inclusions found in the SCN and PVN; amyloid plaques detected in the PVN but not the SCN or SON.
• The SON showed no evidence of amyloid plaques or tau accumulation, indicating resistance to AD pathology.

Conclusions:

• The SCN is particularly vulnerable to early neurodegeneration in AD, contrasting with the PVN's accumulation of pathology without significant neuronal loss.
• The SON demonstrates relative resistance to AD pathology, suggesting differential vulnerability among hypothalamic nuclei.
• These findings highlight the role of intrinsic neuronal properties and local microenvironments in selective vulnerability and resilience mechanisms in Alzheimer's disease.